Dendritic cells (DCs) are myeloid cells bridging the innate and adaptive immune system. By
cross‐presenting tumor‐associated antigens (TAAs) liberated upon spontaneous or therapy …

In the last decade, messenger ribonucleic acid (mRNA)-based drugs have gained great
interest in both immunotherapy and non-immunogenic applications. This surge in interest …

Realizing the immense clinical potential of mRNA-based drugs will require continued
development of methods to safely deliver the bioactive agents with high efficiency and …

RNA therapeutics, such as mRNA, siRNA, and CRISPR–Cas9, present exciting avenues for
treating diverse diseases. However, their potential is commonly hindered by vulnerability to …

Tumors can be classified into distinct immunophenotypes based on the presence and
arrangement of cytotoxic immune cells within the tumor microenvironment (TME). Hot …

Lipid nanoparticles (LNPs) exhibit remarkable mRNA delivery efficiency, yet their majority
accumulate in the liver or spleen after injection. Tissue‐specific mRNA delivery can be …

Using nanostructured drug delivery systems has attracted increasing interest in
immunotherapeutic approaches. The intrinsic immunomodulatory properties and versatility …

Programmed death-ligand 1 (PD-L1) is a promising target for cancer immunotherapy due to
its ability to inhibit T cell activation; however, its expression on various noncancer cells may …

Nanocellulose, a versatile biopolymer renowned for its exceptional physicochemical
attributes including lightweight, biocompatibility, biodegradability, and higher mechanical …

Conventional cancer therapy has major limitations, including non-specificity, unavoidable
side effects, low specific tumor accumulation and systemic toxicity. In recent years, more …